Managing Hypoglycemia (when combined) on Mounjaro (tirzepatide for T2D): The HealthRX.com Step-by-Step Protocol
At a glance
- Main interaction / Insulin and insulin secretagogues such as sulfonylureas [1]
- Label statement / Consider reducing the insulin or sulfonylurea dose when starting Mounjaro [1]
- Severity named in the label / Hypoglycemia, including severe hypoglycemia [1]
- Mounjaro indication / Type 2 diabetes in adults and children 10 years and older; reducing major cardiovascular events in adults with type 2 diabetes at high risk [1]
- Weight loss / Mounjaro is not labeled for weight loss [1]
- SURPASS-6 hypoglycemia / 0.4 vs 4.4 events per patient-year, tirzepatide vs insulin lispro added to insulin glargine [3]
What does the Mounjaro label say about hypoglycemia?
The Mounjaro label lists hypoglycemia with concomitant use of insulin secretagogues or insulin as a warning and precaution. It says patients receiving Mounjaro with an insulin secretagogue, such as a sulfonylurea, or with insulin may have an increased risk of hypoglycemia, including severe hypoglycemia, and that the risk may be lowered by reducing the dose of the sulfonylurea or other insulin secretagogue, or of insulin [1].The drug interactions section gives the same statement for starting treatment: when initiating Mounjaro, consider reducing the dose of the concomitant insulin secretagogue or insulin to reduce the risk of hypoglycemia. The label also says to inform patients using these medicines about the risk and to educate them on the signs and symptoms of hypoglycemia [1].
Why is the combination the focus?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, and the label's hypoglycemia warning is specifically about concomitant use with an insulin secretagogue or insulin [1]. A review of GLP-1-based therapies notes that they slow gastric emptying, which lowers postprandial glucose but also carries potential risks, including hypoglycemia in people on insulin or sulfonylurea therapy [2].What about people already taking basal insulin?
SURPASS-6 randomized 1,428 adults with type 2 diabetes who were taking basal insulin to tirzepatide 5, 10 or 15 mg or to prandial insulin lispro, both added to insulin glargine. Hypoglycemia events (blood glucose below 54 mg/dL or severe hypoglycemia) occurred at 0.4 events per patient-year with pooled tirzepatide and 4.4 with insulin lispro [3]. The label's statement about reducing insulin when starting Mounjaro covers insulin generally [1].How much should the insulin or sulfonylurea dose be reduced?
The label says to consider reducing the dose of the insulin secretagogue or insulin when starting Mounjaro. Its warning and drug interactions sections do not specify a percentage reduction, or a schedule for adjusting those medicines [1].Frequently asked questions
Does Mounjaro by itself cause hypoglycemia?
The Mounjaro label's specific hypoglycemia warning is for use with an insulin secretagogue or insulin, where it says the combination may increase the risk of hypoglycemia, including severe hypoglycemia [1].
Which medicines does the warning cover?
The label names insulin secretagogues, such as sulfonylureas, and insulin [1].
What does the label say about educating patients?
The label says to inform patients using insulin or an insulin secretagogue about the risk and to educate them on the signs and symptoms of hypoglycemia [1].
What about basal insulin?
SURPASS-6 randomized 1,428 adults with type 2 diabetes taking basal insulin to tirzepatide or prandial insulin lispro, both added to insulin glargine; hypoglycemia events were 0.4 per patient-year with tirzepatide and 4.4 with lispro [3].
References
- U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
- Jalleh RJ, Marathe CS, Rayner CK, Jones KL, Umapathysivam MM, Wu T, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024;166(1). Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility
- Rosenstock J, Frías JP, Rodbard HW, Tofé S, Sears E, Huh R, et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023;330(17):1631-1640. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial